Literature DB >> 26134234

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.

Chien-Hung Gow1, Wei-Yu Liao, Yi-Nan Liu, Jin-Yuan Shih.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26134234     DOI： 10.1097/JTO.0000000000000518

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

Review 1.  Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.

Authors:  Bin-Chi Liao; Chia-Chi Lin; James Chih-Hsin Yang
Journal:  Curr Oncol Rep       Date:  2017-01       Impact factor: 5.075

Review 2.  Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.

Authors:  Alia Daoud; Quincy S Chu
Journal:  Front Oncol       Date:  2017-09-29       Impact factor: 6.244

3.  Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report.

Authors:  Yan Gao; Aihong Zheng; Xiuming Zhu; Jia Song; Qian Xue
Journal:  Onco Targets Ther       Date:  2018-12-05       Impact factor: 4.147

Review 4.  Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.

Authors:  Yuequan Shi; Mengzhao Wang
Journal:  Thorac Cancer       Date:  2018-10-31       Impact factor: 3.500
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.